Details

Autor(en) / Beteiligte

• Fernandes Messias, Márcia Cristina
• Mecatti, Giovana Colozza
• Figueiredo Angolini, Célio Fernando
• Eberlin, Marcos Nogueira
• Credidio, Laura
• Real Martinez, Carlos Augusto
• Rodrigues Coy, Cláudio Saddy
• de Oliveira Carvalho, Patrícia

Titel

Plasma Lipidomic Signature of Rectal Adenocarcinoma Reveals Potential Biomarkers

Ist Teil von

• Frontiers in oncology, 2018-01, Vol.7, p.325-325

Ort / Verlag

Switzerland: Frontiers Media S.A

Erscheinungsjahr

2018

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Rectal adenocarcinoma (RAC) is a common malignant tumor of the digestive tract and survival is highly dependent upon stage of disease at diagnosis. Lipidomic strategy can be used to identify potential biomarkers for establishing early diagnosis or therapeutic programs for RAC. To evaluate the lipoperoxidation biomarkers and lipidomic signature in the plasma of patients with RAC (  = 23) and healthy controls (  = 18). Lipoperoxidation was evaluated based on malondialdehyde (MDA) and F -isoprostane levels and the lipidomic profile obtained by gas chromatography and high resolution mass spectrometry (ESI-q-TOF) associated with a multivariate statistical technique. The most abundant ions identified in the RAC patients were those of protonated phosphatidylcholine and phosphatidylethanolamine. It was found that a lisophosphatidylcholine (LPC) plasmalogen containing palmitoleic acid [LPC (P-16:1)], with highest variable importance projection score, showed a tendency to be lower in the cancer patients. A reduction of  3 polyunsaturated fatty acids was observed in the plasma of these patients. MDA levels were higher in patients with advanced cancer (stages III/IV) than in the early stages groups and the healthy group (  < 0.05). No differences in F -isoprostane levels were observed among these groups. This study shows that the reduction in plasma levels of LPC plasmalogens associated with an increase in MDA levels may indicate increased oxidative stress in these patients and identify the metabolite LPC (P-16:1) as a putatively novel lipid signature for RAC.